<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137042</url>
  </required_header>
  <id_info>
    <org_study_id>201907091RINA</org_study_id>
    <nct_id>NCT04137042</nct_id>
  </id_info>
  <brief_title>Metabolomics of Intraoperative Saline and Balanced Crystalloid Infusion</brief_title>
  <official_title>Comparison Between 0.9% Saline and Balanced Crystalloid on Intraoperative Metabolomic Profiles Among Patients Undergoing Major Spine Surgery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different crystalloids, namely 0.9% saline and balanced crystalloid may result in different&#xD;
      metabolomic profile among surgical patients. This study aims to investigate the serum and&#xD;
      urine profiles between patients undergoing major spine surgery using 0.9% saline and balanced&#xD;
      crystalloid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous fluid is mandatory for acute and critically ill patients as well as for surgical&#xD;
      patients. Two crystalloid iv. solutions namely 0.9% saline and balanced crystalloid are the&#xD;
      most commonly administrated. However, early literature suggests that 0.9% saline is&#xD;
      associated with hyperchloremic acidosis, which affects cellular metabolism and may result in&#xD;
      worse prognosis among acute or critically ill patients. However, recent literature in 2018,&#xD;
      including a meta-analysis and a large randomized controlled trial published in the New&#xD;
      England Journal of Medicine revealed neutral or merely slight different clinical outcomes&#xD;
      between 0.9% saline and balanced crystalloids. Therefore, the metabolic differences between&#xD;
      these two fluids may only exist in specific metabolic pathway which may be easily masked by&#xD;
      the complex pathophysiological changes in acute and critically ill patients. These metabolic&#xD;
      alteration may be only identified by precise research t the technology such as liquid&#xD;
      chromatography mass spectrometry, which provides more comprehensive metabolomics profiles. By&#xD;
      comparison, surgical patients undergoing major spine surgery receive a relatively large&#xD;
      amount of intravenous infusion during surgery, and there is not complicated with complex&#xD;
      pathophysiological alteration of cormorbid diseases. Accordingly, this study aim to identify&#xD;
      the metabolomic differences between 0.9% saline and balanced crystalloid among patients&#xD;
      undergoing major spine surgery by using the liquid chromatography mass spectrometry&#xD;
      technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>comparison between two intraoperative iv. fluids</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of metabolites in serum and urine measured by metabolomic mass spectrometry</measure>
    <time_frame>2-6 hours</time_frame>
    <description>Serum and urine samples will be collected twice (before and immediately after surgery) in each patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative hemodynamic stability</measure>
    <time_frame>2-6 hours</time_frame>
    <description>Incidence of intraoperative hypotension between the two fluids.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metabolomics</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraoperative fluid therapy by using 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced crystalloid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraoperative fluid therapy by using balanced crystalloid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intraoperative fluid therapy is administrated by using 0.9% saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced crystalloid</intervention_name>
    <description>Intraoperative fluid therapy is administrated by using balanced crystalloid</description>
    <arm_group_label>Balanced crystalloid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. age between 40 and 65 year-old&#xD;
&#xD;
          2. major lumbar spine surgery (spinal fusion„ÄÅmultiple levels or expected operation time&gt;&#xD;
             2 hr)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Preoperative organ dysfunction, such as impaired liver function, eg. AST or ALT &gt;100;&#xD;
             liver cirrhosis &gt; Child B class; Impaired renal function, eGFR&lt; 60 ml/min/1.73 m2;&#xD;
             cardiac dysfunction, such as heart failure &gt; NYHA class II, coronary arterial disease&#xD;
&#xD;
          2. Preoperative use of medications which interfere with liver, renal or electrolyte&#xD;
             metabolism, such as statin or digoxin&#xD;
&#xD;
          3. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Yu Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun-Yu Wu</last_name>
    <phone>886972651142</phone>
    <email>longersolo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Chun-Yu</last_name>
      <phone>0972653376</phone>
      <email>longersolo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolomics</keyword>
  <keyword>Fluid therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

